Anderson Erik D, Alishahedani Mohammadali E, Myles Ian A
Epithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States.
Front Allergy. 2020 Dec;1. doi: 10.3389/falgy.2020.628381. Epub 2020 Dec 18.
Atopic diseases, particularly atopic dermatitis (AD), asthma, and allergic rhinitis (AR) share a common pathogenesis of inflammation and barrier dysfunction. Epithelial to mesenchymal transition (EMT) is a process where epithelial cells take on a migratory mesenchymal phenotype and is essential for normal tissue repair and signal through multiple inflammatory pathways. However, while links between EMT and both asthma and AR have been demonstrated, as we outline in this mini-review, the literature investigating AD and EMT is far less well-elucidated. Furthermore, current studies on EMT and atopy are mostly animal models or studies on cell cultures or tissue biopsies. The literature covered in this mini-review on EMT-related barrier dysfunction as a contributor to AD as well as the related (perhaps resultant) atopic diseases indicates a potential for therapeutic targeting and carry treatment implications for topical steroid use and environmental exposure assessments. Further research, particularly studies, may greatly advance the field and translate into benefit for patients and families.
特应性疾病,尤其是特应性皮炎(AD)、哮喘和过敏性鼻炎(AR),具有炎症和屏障功能障碍的共同发病机制。上皮-间质转化(EMT)是上皮细胞呈现迁移性间质表型的过程,对正常组织修复至关重要,并通过多种炎症途径进行信号传导。然而,正如我们在本综述中所概述的,虽然EMT与哮喘和AR之间的联系已得到证实,但研究AD与EMT的文献却远未得到充分阐明。此外,目前关于EMT与特应性的研究大多是动物模型或细胞培养或组织活检研究。本综述中涵盖的关于EMT相关屏障功能障碍作为AD以及相关(可能是由此导致的)特应性疾病的一个促成因素的文献表明了治疗靶点的潜力,并对局部类固醇的使用和环境暴露评估具有治疗意义。进一步的研究,尤其是临床试验,可能会极大地推动该领域的发展,并为患者和家庭带来益处。